AstraZeneca & Roche
11 shared events · Importance 4 · Last updated Sep 22, 2026
Live sentiment trends, interaction importance charts, and action volume tracking available on the
Ergen Dashboard
Regulatory
AstraZeneca: AstraZeneca benefits from the expanded label of the VENTANA MMR RxDx Panel as it identifies patients eligible for its Durvalumab and Olaparib therapies, potentially increasing the drugs' market reach.
Roche: Roche received IVDR approval for its VENTANA MMR RxDx Panel, expanding its use across multiple cancer types and therapies, which is a positive development for the company's diagnostics division and market position.
Jun 11, 2026 · 6 articles
Regulatory
AstraZeneca: One of the nine signatories of the open letter urging the European Union to boost pharmaceutical investment and speed up trials. The appeal signals concern over European competitiveness but does not change its near-term financial outlook.
Roche: One of the nine companies whose chairs signed the letter seeking faster trials, IP protections and fiscal flexibility in Europe. The move highlights its stake in European research and development competitiveness.
Sep 22, 2026 · 6 articles
Tech
AstraZeneca: AstraZeneca is the central entity of the event; its breast cancer drug Etcamah failed a late-stage trial, sending its U.S.-listed shares down 3% in aftermarket trading. The setback is seen by analysts as manageable and largely anticipated, with the long-term investment case intact.
Roche: Roche's similar drug combination failed to significantly slow disease progression in March, a prior event that analysts cited as context making the AstraZeneca setback well anticipated.
Sep 11, 2026 · 6 articles
Business
AstraZeneca: AstraZeneca is mentioned as a developer of an approved BTK inhibitor, Calquence, which is a competitor to bexobrutideg.
Roche: Roche has entered into an exclusive licensing and collaboration agreement with Nurix Therapeutics to co-develop and co-commercialize bexobrutideg, strengthening its hematology portfolio and expanding into immunology and neurology. This deal positions Roche to potentially lead in the BTK degrader market.
Jun 07, 2026 · 22 articles
Tech
AstraZeneca: AstraZeneca>>> developed Tagrisso, a tyrosine kinase inhibitor used to treat Michelle Vacca>>>'s EGFR-mutated lung cancer.
Roche: Roche>>> developed Herceptin, one of the first antibody drugs used to treat HER2-positive breast cancer, as exemplified by Cathy Smithwick>>>'s treatment.
Jun 03, 2026 · 6 articles
Business
AstraZeneca: AstraZeneca's Imfinzi faces potential biosimilar competition, which could erode its market share, though the impact is long-term and uncertain.
Roche: Roche's Hemlibra faces potential biosimilar competition, which could affect its sales, though the impact is long-term and uncertain.
Aug 21, 2026 · 6 articles
Business
AstraZeneca: AstraZeneca is mentioned as a former employer of both Borellini and Iannone; not directly affected by this event.
Roche: Roche is mentioned as the parent of F. Hoffmann-La Roche — Genentech; not directly affected by this event.
Jul 13, 2026 · 6 articles
Business
AstraZeneca: AstraZeneca is cited as a peer whose total shareholder returns have outpaced Novartis since Narasimhan became CEO, highlighting relative underperformance concerns.
Roche: Roche is referenced as a Swiss rival whose total shareholder returns under the same period were lower than Novartis', providing context for investor patience with management.
Sep 08, 2026 · 21 articles
Tech
AstraZeneca: Segev received honoraria; unrelated.
Roche: Segev received honoraria; unrelated.
Sep 04, 2026 · 7 articles
ERGEN INTELLIGENCE
Explore this relationship live
Track how AstraZeneca and Roche interact across events, view sentiment trends, and discover connected entities.
Open Dashboard